located in rochester, ny, vaccinex is a privately held, clinical-stage biotechnology company engaged in the discovery and development of human therapeutic monoclonal antibodies, therapeutic vaccines and other biologic products to treat serious diseases with unmet needs, including cancer, multiple sclerosis, and other autoimmune diseases. we conduct discovery research in-house and in collaboration with world-class academic institutions and biotechnology companies, and have an experienced in-house drug development management team to advance our pre-clinical and clinical stage biopharmaceutical development programs. our development team is led by seasoned industry veterans with both operational and executive level biopharmaceutical industry experience in therapeutic biologics research, manufacturing, quality assurance, quality control, toxicology, pharmacology, drug regulatory affairs, and clinical affairs. we are committed to innovation in the way we approach drug discovery and develop
Company profile
Ticker
VCNX
Exchange
Website
CEO
Maurice Zauderer
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
VACCINEX INC
SEC CIK
Corporate docs
IRS number
161603202
VCNX stock data
Latest filings (excl ownership)
10-K/A
2023 FY
Annual report (amended)
25 Apr 24
EFFECT
Notice of effectiveness
17 Apr 24
424B3
Prospectus supplement
16 Apr 24
D
$2.46 mm in equity / options / securities to be acquired, sold $1.24 mm, 3 investors
12 Apr 24
D
$3.50 mm in equity / options / securities to be acquired, sold $1.75 mm, 1 investor
12 Apr 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
12 Apr 24
D
$1.47 mm in options / securities to be acquired, 4 investors
12 Apr 24
ARS
2023 FY
Annual report to shareholders
2 Apr 24
DEF 14A
Definitive proxy
2 Apr 24
S-3
Shelf registration
2 Apr 24
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 127.00 k | 127.00 k | 127.00 k | 127.00 k | 127.00 k | 127.00 k |
Cash burn (monthly) | 593.67 k | 588.25 k | 1.94 mm | 1.92 mm | 1.03 mm | 1.52 mm |
Cash used (since last report) | 4.09 mm | 4.05 mm | 13.39 mm | 13.20 mm | 7.10 mm | 10.46 mm |
Cash remaining | -3.96 mm | -3.92 mm | -13.26 mm | -13.07 mm | -6.97 mm | -10.34 mm |
Runway (months of cash) | -6.7 | -6.7 | -6.8 | -6.8 | -6.8 | -6.8 |
Institutional ownership, Q2 2023
13F holders | Current |
---|---|
Total holders | 25 |
Opened positions | 4 |
Closed positions | 4 |
Increased positions | 6 |
Reduced positions | 4 |
13F shares | Current |
---|---|
Total value | 986.39 mm |
Total shares | 33.49 mm |
Total puts | 300.00 |
Total calls | 12.00 k |
Total put/call ratio | 0.0 |
Largest owners | Shares | Value |
---|---|---|
FCMI Parent | 26.25 mm | $10.50 mm |
Maurice Zauderer | 4.41 mm | $2.08 mm |
AIGH Capital Management | 1.35 mm | $472.16 mm |
Vanguard | 732.86 k | $260.90 mm |
Geode Capital Management | 250.19 k | $89.07 mm |
Worth Venture Partners | 138.80 k | $49.41 mm |
Citadel Advisors | 103.08 k | $36.70 mm |
STT State Street | 71.40 k | $25.42 mm |
Renaissance Technologies | 46.28 k | $16.00 k |
Tower Research Capital | 31.42 k | $11.18 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
19 Apr 24 | Friedberg Albert | Common Stock | Buy | Acquire P | Yes | No | 4.73 | 282 | 1.33 k | 560,597 |
28 Mar 24 | Maurice Zauderer | Common Stock | Grant | Acquire A | Yes | No | 7.77 | 38,610 | 300.00 k | 138,138 |
28 Mar 24 | Maurice Zauderer | Warrant Common Stock | Grant | Acquire A | Yes | No | 7.77 | 38,610 | 300.00 k | 38,610 |
28 Mar 24 | Friedberg Albert | Common Stock | Grant | Acquire A | Yes | No | 7.77 | 102,960 | 800.00 k | 560,315 |
28 Mar 24 | Friedberg Albert | Warrant Common Stock | Grant | Acquire A | Yes | No | 7.77 | 102,960 | 800.00 k | 102,960 |
20 Mar 24 | Maurice Zauderer | Stock Option Common Stock | Grant | Acquire A | No | No | 9.15 | 1,877 | 17.17 k | 1,877 |
20 Mar 24 | Jill Sanchez | Stock Option Common Stock | Grant | Acquire A | No | No | 8.32 | 805 | 6.70 k | 805 |
News
12 Health Care Stocks Moving In Thursday's Pre-Market Session
25 Apr 24
Vaccinex Q4 EPS $(0.33) Up From $(23.10) YoY
2 Apr 24
Vaccinex Announces It Has Entered Into Eight New Antibody Discovery Agreements Integrating Use Of Its Proprietary ActivMAb Platform To Select Antibodies Against Difficult-To-Drug Transmembrane Protein Targets
21 Feb 24
Why Vaccinex (VCNX) Stock Is Trading Lower
15 Feb 24
12 Health Care Stocks Moving In Wednesday's After-Market Session
14 Feb 24
Press releases
Vaccinex, Inc. Announces $1.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules
27 Mar 24
Vaccinex Announces Multiple New Agreements for Access to ActivMAb® Antigen Virus Technology
21 Feb 24
Vaccinex Announces Pricing of $3.7 Million PIPE Financing
7 Feb 24